

Date: 18th February, 2019

The Manager,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Sub.: Submission of Advertisement clippings of Extract of Standalone Unaudited quarterly results for the Quarter and nine months ended 31st December, 2018

Dear Sirs,

In terms of Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached a copy of the advertisement clipping of Extract of Standalone Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2018 published in Financial Express (English daily) and Financial Express (Gujarati daily) dated 16th February, 2019 which were approved at the Board Meeting of the Company held on Thursday, the 14th day of February, 2019.

Thanking You,

Yours Faithfully,

For Parmax Pharma Limited



Yash J. Vora
Company Secretary

Encl: As above

KAMDA CONSTRUCTIONS LTD.
 SO:-
Mr. Naresh Karda
 Managing Director
 Dir. 07741279

Registered Off. : 2nd Fl. Gulmohar Station, Above Bannest Bank, Samarth Nagar, Mahatma Nagar, Nashik, MH - 422 005.
 Corporate Off. : Sakrton Complex, Tala Road, Opposite Mahadham, Nashik Road, Nashik, MH - 422 101
 Phone : 0253 - 233790 / 2465436. Mail : carda@kardaconstruction.com | Web : www.kardaconstruction.com

જાહેરાત/સંબંધિત સંસ્થાના નિયંત્રક/સંબંધિત સંસ્થાના નિયંત્રક(શ્રી) અને નિયંત્રક સંસ્થાના
 સંબંધિત ના સંબંધિત છે. (સંબંધિત સંસ્થાના)
 નિયંત્રક/સંબંધિત સંસ્થાના નિયંત્રક/સંબંધિત સંસ્થાના નિયંત્રક(શ્રી) અને નિયંત્રક સંસ્થાના
 સંબંધિત ના સંબંધિત છે. (સંબંધિત સંસ્થાના)
 નિયંત્રક/સંબંધિત સંસ્થાના નિયંત્રક/સંબંધિત સંસ્થાના નિયંત્રક(શ્રી) અને નિયંત્રક સંસ્થાના
 સંબંધિત ના સંબંધિત છે. (સંબંધિત સંસ્થાના)

special Chief Engineer, WND,
 Middle Cauvery Basin Circle, Trichy.
 DIPR/1186/Tender/2019

KUSHAL LIMITED
 Regd. Office: Kushal House, Plot No. 115, Off. C.G Road, Navrangpura, Ahmedabad-380009, Gujarat. Phone: 079-26408027
 CIN : L14116GZ0009PLC021472 Email: cs@kushallimited.com website: www.kushallimited.com

Extract of Unaudited Financial Results for the Quarter/Nine Months ended December 31, 2018
 (Rs. in Lakhs except EPS)

Sl. No.	Particulars	STANDALONE FINANCIAL RESULT				CONSOLIDATED FINANCIAL RESULT					
		Quarter ended 31.12.2018 Unaudited	3 Months Ended 31.12.2018 Unaudited	3 Months Ended 31.12.2017 Unaudited	Year ended 31.12.2018 Unaudited	Quarter ended 31.12.2018 Unaudited	3 Months Ended 31.12.2018 Unaudited	3 Months Ended 31.12.2017 Unaudited	Year ended 31.12.2018 Unaudited		
1.	Total Revenue	3862.51	47889.75	14301.03	78414.14	103096.53	3862.53	57645.69	62642.05	206901.57	233783.05
2.	Net Profit / (Loss) for the period (Before Tax, Exceptional and/or Extraordinary items)	442.11	790.71	1184.11	3171.24	3507.35	411.22	2604.92	3895.30	11810.94	11774.98
3.	Net Profit / (Loss) for the period before tax (After Exceptional and/or Extraordinary items)	442.11	790.71	1184.11	3171.24	3507.35	411.22	2604.92	3895.30	11810.94	11774.98
4.	Net Profit / (Loss) for the period after tax (After Exceptional and/or Extraordinary items)	280.84	510.04	735.34	2355.15	2771.48	249.95	2323.49	3435.69	10880.88	10965.77
5.	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	280.84	510.04	735.34	2355.15	2771.48	249.95	2323.49	3435.69	10880.88	10965.77
6.	Paid Up Equity Share Capital (Face value ₹ 2)	4745.33	4745.33	4745.33	4745.33	4745.33	4745.33	4745.33	4745.33	4745.33	4745.33
7.	Other Equity excluding Revaluation Reserve	0.00	0.00	0.00	0.00	8186.31	0.00	0.00	0.00	0.00	28902.10
8.	Earnings Per Share (of ₹ 2/- each) (for continuing and discontinued operations)										
	1. Basic	0.12	0.21	0.31	0.99	1.17	0.11	0.98	1.45	4.59	4.62
	2. Diluted	0.12	0.21	0.31	0.99	1.17	0.11	0.98	1.45	4.59	4.62

Note:
 1. The Financial result of the company have been prepared in accordance with Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant transitional provisions.
 2. As per Indian Accounting Standard 108 "Operating Segments", the company has reported "Segment Information" as described below:
 Geographical Segments include -
 1. Kushi Limited, India
 2. Kushi India Pte Ltd, Singapore
 3. Kushi Health Forwade FZE, Ajman Free Zone, U.A.E.
 Station Forwade (Labuan) Private Limited, Malaysia (Wholly Owned Subsidiary) and Kushi Integrated Industrial Park LLP (Wholly Owned LLP), are yet to commence its business operations.
 3. The figures for the corresponding previous period have been regrouped/reclassified wherever necessary to make them comparable.
 4. The Board of Directors, in its meeting held on May 1, 2017, approved a Scheme of Arrangement of Kushi Infrastructure Private Limited, Ahapora Paper Mills Private Limited, Kushi Health Care Private Limited and Kushi Health Care Private Limited with Kushi Limited (Formerly known as Kushi Tradex Limited) and their respective shareholders and creditors. The company has received approval of
 National Company Law Tribunal on 09.02.2018 vide its order CP (CA) No. 146/2018 in CA (CA) No. 198/2015 (2015) TNJM0218. But due to pendency of the accompanying statement for the Quarter and Period ended December 31, 2018 have been prepared without giving any effect of the sanctioned scheme. The financials giving effect of the sanctioned scheme will be submitted in due course of time.
 5. Committee of Creditors (CoC) of Rainbow Papers Limited (in Corporate Insolvency Resolution Process) constituted as per law has approved Resolution Plan submitted by the company by e-voting process as per extant provisions of Insolvency and Bankruptcy Code, 2016. The company is in the process of completing the necessary legal and regulatory compliances with NCLT for amalgamation of Rainbow Papers Limited into Kushi Limited under Insolvency and Bankruptcy Code, 2016. The accompanying statements for the Quarter and Period ended December 31, 2018, have been prepared without giving any effect of the transaction.
 6. The above is an extract of the detailed format for the quarter ended unaudited financial results filed with the stock exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format for the quarter ended unaudited financial result are available on the website of Stock Exchange www.bseindia.com and also available on the Company's website www.kushallimited.com.
 For KUSHAL LIMITED
 SO:-
Sandeep Agrawal
 (Chairman & Managing Director)
 (DIN: 00236648)

Date: February 14, 2019
 Place: AHMEDABAD

PARMAX PHARMA LIMITED
 Reg. off : Plot No. 20, Rajkot Gondal National Highway No.27,
 Hadamtala, Tal. Kotda Sangani, Dist. Rajkot (Gujarat) - 360311, INDIA
 (CIN: L24231GJ1994PLC023504 Web : www.parmaxpharma.com, E-mail - parmaxpharma@gmail.com)

Extract of Unaudited Financial Results for the Quarter Nine Months Ended 31/12/2018
 (Rs. In Lakh)

Sr. No.	Particulars	For the Quarter Ended			Nine Months Ended	
		31/12/2018	30/09/2018	31/12/2017	31/12/2018	31/12/2017
1	Total income from operations (net)	187.54	353.95	257.85	880.19	877.15
2	Net Profit / (Loss) for the period (before tax, Exceptional and / or Extraordinary items)	-29.14	-55.44	3.69	-78.45	-28.23
3	Net Profit / (Loss) for the period before tax (After Exceptional and / or Extraordinary items)	-29.14	-55.44	3.69	-78.45	-28.23
4	Net Profit / (Loss) for the period After tax (After Exceptional and / or Extraordinary items)	-29.14	-55.44	3.69	-78.45	-28.23
5	Total Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.00
6	Equity Share Capital	374.13	374.13	374.13	374.13	374.13
7	Reserves (excluding Revaluation Reserve as shown in the balance Sheet of previous year)	-29.14	-38.76	-17.74	-67.90	-17.74
8	Earning Per Share (before extraordinary items) (of Rs.10/- each)					
	Basic EPS Diluted EPS	-0.78	-1.48	0.10	-2.10	-0.75

Note: The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the Stock Exchange websites (www.bseindia.com) & on Company's website (www.parmaxpharma.com)

Place : Hadamtala
 Date : 14th February, 2019
 For, Parmax Pharma Limited
 sd/-
Alkesh Gosalia
 Director
 Din No. : 01130615

F.E (Guj) 15x20 JP.GU - 15/1/19